Molecular MOLN 深 滬
等待開盤 11-04 09:30:00 美东时间
3.09
-0.390
-11.21%
華盛通- 最 高3.20
- 今 開3.18
- 成交量 2378股
- 最 低 3.09
- 昨 收 3.4801
- 總市值 1.18亿
- 52周最高 5.36
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 3.09
- 委 比 25.91%
- 總股本 3830.52万
- 歷史最高 32.04
- 量 比 1.26
- 振 幅 3.16%
- 歷史最低 3.09
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
MacroGenics, Inc. announced the appointment of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors to its Board of Directors, effective October 30, 2026. Both bring extensive oncology drug development experience, which will support the company's pipeline advancement and long-term strategic goals. Dr. Kuriakose has over a decade of experience in oncology and metabolic disease drug development, most recently as Chief Medica...
11-03 21:05
Molecular Partners收涨1.42%，成交额6237美元
10月31日，Molecular Partners（MOLN）收涨1.42%，报3.58美元，成交额6237美元，市值1.37亿美元。 行情数据 • 开盘价：...
10-31 06:51
4D Molecular’s 4SIGHT Trial Targets a Durable Edge in Diabetic Eye Care
4D Molecular Therapeutics, Inc. ($FDMT) announced an update on their ongoing cl...
10-31 00:31
CareDx’s MERIT Trial: New Data‑Driven Approach to Heart Transplant Rejection
CareDx Inc ($CDNA) announced an update on their ongoing clinical study. The Mol...
10-30 00:31
Molecular Partners Q3 EPS $(0.38) Beats $(0.46) Estimate
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.46) by 17.39 percent. This is a 76.97 percent increase over losses of $(1.65) per share from the same period last year.
10-29 21:50
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
Purple Biotech's IM1240, a tri-specific antibody from its CAPTN-3 platform, has been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 20, 2026. The presentation will highlight IM1240's multi-arm mechanism, NKG2A engagement, pharmacokinetics, and safety in treatment-resistant tumor models. Purple Biotech aims to advance IM1240 toward clinical trials in 2027, pending regulatory approval. The presentati...
10-29 13:00
Molecular Partners收跌2.98%，成交额1.27万美元
10月23日，Molecular Partners（MOLN）收跌2.98%，报3.61美元，成交额1.27万美元，市值1.38亿美元。 行情数据 • 开盘价...
10-23 06:55
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
Lexicon Pharmaceuticals highlighted findings from two preclinical studies showing sotagliflozin's beneficial effects on hypertrophic cardiomyopathy (HCM) and thrombosis. The dual SGLT1/SGLT2 inhibitor improved cardiac function, reduced fibrosis, and decreased platelet activation without affecting normal hemostasis. These results support its potential in treating HCM and reducing cardiovascular risks. Lexicon is currently testing sotagliflozin in ...
10-21 12:30
Molecular Partners收跌2.47%，成交额2485美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:57
